https://orcid.org/0000-0002-8370-9562
References
- Smeeding J, Malone DC, Ramchandani M, et al. Biosimilars: considerations for payers. P T. 2019 Jan;44(2):54–63. doi: 10.1056/NEJMp1107285
- ‘Generic’ biologic drugs appear comparable to brand-name counterparts. Johns Hopkins bloomberg school public health. 2016. https://publichealth.jhu.edu/2016/generic-biologic-drugs-appear-comparable-to-brand-name-counterparts#:~:text=They%20took%20the%20data%20from,effectiveness%20as%20their%20branded%20counterparts
- NHS. Biosimilar medicines. England: NHS. https://www.england.nhs.uk/medicines-2/biosimilar-medicines/
- Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939. doi: 10.1016/j.semarthrit.2021.11.009
- van der Plas RM, Hoefnagel MHN, Hillege HL, et al. Pragmatic rules for comparability of biological medicinal products. Biologicals. 2020 Jan;63:97–100. doi: 10.1016/j.biologicals.2019.11.002
- Padda IS, Bhatt R, Rehman O, et al. Biosimilars use in medicine for inflammatory diseases. Treasure Island, FL, United States of America: StatPearls; 2023.
- Blauvelt A, Lacour JP, Fowler JF, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018 Sep;179(3):623–631.
- Mysler E, Azevedo VF, Danese S, et al. Biosimilar-to-biosimilar switching: what is the rationale and Current experience? Drugs. 2021 Nov;81(16):1859–1879. doi: 10.1007/s40265-021-01610-1
- Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017 Feb;76(2):346–354. doi: 10.1136/annrheumdis-2015-208783
- Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017 Feb;76(2):355–363. doi: 10.1136/annrheumdis-2015-208786
- De K. Impact of biosimilars on treatment landscape in US and EU [Internet]. 2023 [cited 2024 Jan 23]. Available from: https://www.aranca.com/knowledge-library/articles/business-research/impact-of-biosimilars-on-treatment-landscape-in-us-and-eu
- Kay J, Schoels MM, Dörner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018 Feb;77(2):165–174. doi: 10.1136/annrheumdis-2017-211937
- Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):S685–S699. doi: 10.1136/annrheumdis-2019-216655
- Bridges SL, White DW, Worthing AB, et al. The science behind biosimilars. Arthritis & Rheumat. 2018 Mar;70(3):334–344.
- Barbier L, Vulto AG. Interchangeability of Biosimilars: overcoming the final hurdles. Drugs. 2021 Nov;81(16):1897–1903. doi: 10.1007/s40265-021-01629-4
- de Oliveira Ascef B, Almeida MO, de Medeiros-Ribeiro AC, et al. Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis. Sci Rep. 2023 Aug;13(1):13699. doi: 10.1038/s41598-023-40222-5
- Allocati E, Godman B, Gobbi M, et al. Switching among biosimilars: a review of clinical evidence. Front Pharmacol. 2022 Aug 13;13. doi: 10.3389/fphar.2022.917814
- Cohen HP, Hachaichi S, Bodenmueller W, et al. Switching from one biosimilar to another biosimilar of the same reference biologic: a systematic review of studies. BioDrugs. 2022 Sep;36(5):625–637. doi: 10.1007/s40259-022-00546-6
- Feagan BG, Marabani M, Wu JJ, et al. The challenges of switching therapies in an evolving multiple biosimilars landscape: a narrative review of Current evidence. Adv Ther. 2020 Nov;37(11):4491–4518. doi: 10.1007/s12325-020-01472-1
- Gasteiger C, Gasteiger N, Petrie KJ. Pharmacists’ confidence in explaining biosimilars to patients before a nationwide medicine change: a cross-sectional study. Explor Res Clin Soc Pharm. 2022;8:100199. doi: 10.1016/j.rcsop.2022.100199.
- Barbosa CMM, Rodríguez de Castro B, Labeaga Beramendi Y, et al. Patient satisfaction survey: substitution of reference etanercept with a biosimilar product. Eur J Hosp Pharm Sci Pract. 2021 Mar;28(2):109–111. doi: 10.1136/ejhpharm-2019-001999